The drug is designed to concurrently inhibit the same molecular targets of breast cancer drug, Herceptin, and colon cancer drug, Erbitux. There is currently no single drug on the market that selectively inhibits both of these targets (ErbB-2 and EGFR). As such, the company believes that the drug will provide enhanced efficacy in the treatment of cancer patients.
Oral administration of ARRY-334543 in preclinical models of human breast, lung, or epidermal carcinoma tumors resulted in significant anti-tumor activity.
“Advancing ARRY-334543 into clinical trials is a significant achievement for Array and further demonstrates our ability to invent novel therapies for cancer patients,” said Dr Kevin Koch, president and chief scientific officer. “Our goal is to continue building the industry’s leading clinical pipeline of small molecule drugs, driving Array’s future growth.”
Array plans to commence the phase I clinical trial in the autumn.